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Abstract
Objective. MTX is widely used to treat synovitis in PsA without supporting trial evidence. The aim of our
study was to test the value of MTX in the first large randomized placebo-controlled trial (RCT) in PsA.
Methods. A 6-month double-blind RCT compared MTX (15 mg/week) with placebo in active PsA. The
primary outcome was PsA response criteria (PsARC). Other outcomes included ACR20, DAS-28 and their
individual components. Missing data were imputed using multiple imputation methods. Treatments were
compared using logistic regression analysis (adjusted for age, sex, disease duration and, where appro-
priate, individual baseline scores).
Results. Four hundred and sixty-two patients were screened and 221 recruited. One hundred and nine
patients received MTX and 112 received placebo. Forty-four patients were lost to follow-up (21 MTX, 23
placebo). Twenty-six patients discontinued treatment (14 MTX, 12 placebo). Comparing MTX with placebo
in all randomized patients at 6 months showed no significant effect on PsARC [odds ratio (OR) 1.77, 95%
CI 0.97, 3.23], ACR20 (OR 2.00, 95% CI 0.65, 6.22) or DAS-28 (OR 1.70, 95% CI 0.90, 3.17). There were
also no significant treatment effects on tender and swollen joint counts, ESR, CRP, HAQ and pain. The
only benefits of MTX were reductions in patient and assessor global scores and skin scores at 6 months
(P= 0.03, P<0.001 and P= 0.02, respectively). There were no unexpected adverse events.
Conclusions. This trial of active PsA found no evidence for MTX improving synovitis and consequently
raises questions about its classification as a disease-modifying drug in PsA.
Trial registration. Current Controlled Trials, www.controlled-trials.com, ISRCTN:54376151.
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Introduction
Randomized controlled trials (RCTs) involving placebos
help identify if new treatments are effective. They are also
crucial in identifying widely used standard treatments that
are actually ineffective [1]. Oral MTX has become a stand-
ard treatment for the PsA and is recommended in all recent
guidelines [26]. Furthermore, in active PsA, the UK
National Institute for Health and Clinical Excellence (NICE)
recommends MTX be used before treatments of proven
effectiveness, notably TNF inhibitors [7]. However, all
these recommendations have been made on the basis of
experts’ consensus. The efficacy of oral MTX in PsA has
not been convincingly proven in a placebo-controlled RCT.
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Active PsA should be treated by drugs or biologic treat-
ments that reduce joint inflammation, lower acute-phase
markers and improve disability. In RA, such drugs are
grouped together as DMARDs. Biologics, like TNF inhibi-
tors, are highly effective in PsA; their value has been
shown in a large number of placebo-controlled RCTs
[812]. LEF has also been shown to be effective in a
placebo-controlled RCT [13]. There is only weak evidence
that other conventional drugs like gold injections and SSZ
are effective and there is no definitive RCT evidence for
oral MTX.
MTX can cause serious adverse events [14, 15]. Its con-
tinuing widespread use in PsA is questionable in the ab-
sence of supporting evidence from placebo-controlled
RCTs. The Methotrexate in Psoriatic Arthritis (MIPA) trial
specifically addresses this previously unresolved
question.
Methods
Trial design
MIPA was a 6-month, double-blind, parallel-group RCT in
which patients with active PsA were randomized to re-
ceive MTX (target dose 15 mg/week) or matched placebo.
The allocation ratio of active to placebo treatment
was 1 : 1.
Patients
MIPA enrolled males and females aged at least 18 years
with PsA currently attending UK specialist rheumatology
clinics.
Inclusion criteria
These comprised: (i) clinically apparent psoriasis (skin or
nails) and active inflammatory synovitis involving at least
one peripheral joint (adapted from the two mandatory cri-
teria of Bennett [16], following the approach of Gladman
[17] and Salvarani et al. [18]); (ii) a constant level of NSAID
therapy for at least 1 month; (iii) previous DMARD therapy
discontinued for at least 1 month and (iv) willing and able
to give informed consent.
Exclusion criteria
These comprised: (i) other inflammatory arthropathies or
arthritis mutilans; (ii) systemic steroid therapy currently or
within the last 3 months; (iii) previous or current treatment
with MTX; (iv) other serious medical disorders including
liver, renal and cardiac disease; (v) women of childbearing
potential not taking adequate contraceptive precautions;
and (vi) abnormal full-blood counts and liver function tests
or other contraindications to MTX therapy.
Treatments
Experimental treatment
Patients were seen monthly to adjust their trial medication
and for safety monitoring. MTX was given initially at
7.5 mg/week, increased at 4 weeks to 10 mg/week and
at 8 weeks to the target dose of 15 mg/week. In patients
with persistently active disease, the dosage could be
increased at the discretion of the supervising rheuma-
tologist to 20 mg/week at 4 months and 25 mg/week at
5 months.
Control treatment
Patients received matched placebos that were increased
similarly.
Concomitant therapy
All patients received oral folic acid (5 mg weekly) and
anti-emetic therapy as needed. They continued their cur-
rent NSAIDs and analgesics at unchanged dosages. Oral
or i.m. steroids were not used and only one IA steroid was
allowed.
Outcomes
Patients were assessed at baseline, 3 and 6 months. The
primary outcome measure was the PsA response criteria
(PsARC) [19]. Global secondary outcome assessments
comprised ACR 20% improvement criteria (ACR20) [20]
and DAS for 28 joints (DAS-28) [21]. Individual secondary
outcome measures comprised swollen and tender joint
counts (66/68 joints based on European League Against
Rheumatism (EULAR)/ACR standard methods) [22]; pain
score, patient global assessment and assessor global as-
sessment (using 100-mm visual analogue scores); ESR
and CRP; function assessed using the HAQ; PsA skin
index (PASI) and the nail disease score of Jones et al.
[23]; withdrawal from treatment and adverse reactions.
Sample size
The initial sample size was based on the study of SSZ in
PsA by Clegg et al. [19], which showed that 45% of pa-
tients taking placebo responded to treatment using the
PsARC composite index. We considered a 66% response
rate for active treatment (50% increased response rate)
would constitute a relevant treatment effect. While MIPA
was ongoing and since the Clegg trial was published, sev-
eral more RCTs were completed using the PsARC
[13, 2426]. Based on these new data the MIPA Data
and Ethics Committee recommended reducing the re-
sponse rates for placebo to 35% and reducing the
active response rate to 59%; these were average reported
response rates for placebo and active treatment in trials of
potential DMARDs in PsA. To detect a difference at the
5% level with 90% power between active treatment with a
response rate of 59% and placebo treatment with a re-
sponse rate of 35% requires enrolling 89 patients per
group. Allowing for a 20% drop out rate, this meant re-
cruiting 220 cases. The sample size was defined following
the approach recommended by Machin et al. [27], and the
sample size calculation checked against their most recent
recommendations.
Randomization, sequence generation, allocation
concealment and implementation
Patients were randomly allocated to receive MTX or pla-
cebo. The allocation sequence was generated by the trial
statistician using random number tables. Randomization,
stratified by centre, used random treatment assignment in
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blocks of four. In each centre randomization numbers
were assigned to patients in chronological order as they
passed their screening assessments. Metrologists and the
trial coordinator were unaware of the allocation sequence.
Treatment assignments were in a locked cabinet in the
co-ordinating centre pharmacy for emergency access.
The MTX and placebo were identical in appearance.
They were pre-packed in identical containers and con-
secutively numbered for patients by centre according to
the randomization schedule. Each patient received the
treatment in the corresponding pre-packed container.
Statistical methods
All data management and analyses were done using
Stata, version 11.0 (StataCorp, College Station, TX,
USA) and the R statistical package (R Development
Core Team, 2008). Baseline characteristics were summar-
ized by randomized group. Descriptive summary statistics
of each group were presented as mean (S.D.) for continu-
ous normally distributed and median and interquartile
range for not normally distributed outcome variables and
frequencies and percentages for categorical variables.
Initial statistical analysis was blinded with the statistician
unaware of the treatment groups.
All participants had observations at baseline. However,
some subjects had missing data on the outcome variables
at 3 and 6 months or both. All missing data were imputed
regardless of the reason(s) the data were missing. For
the subjects who had missing outcomes at 3 months,
the baseline outcomes and other covariates (treatment
group, sex, age and disease duration) were used to
impute the missing data at 3 months. For the subjects
who had missing outcomes at 6 months, baseline and
3-month outcomes with covariates were used to impute
the missing values. If the outcome variables were missing
at 3 and 6 months then the outcome variables at 3 months
were imputed first, followed by the outcomes at 6 months.
Assuming unobserved measurements were missing at
random, we imputed missing data by multiple imputation
using chained equations with 20 cycles, where at the end
of the cycle one imputed data set is created and the pro-
cess was repeated to create 20 imputed data sets. The
20 data sets were separately analysed and the results
combined using Rubin’s rules [2830], and therefore the
estimates and S.E.s presented here are the combined
ones. As an additional check of the robustness of the
analyses performed to the missing-at-random assump-
tion, we further analysed the individual component data
that comprise the PsARC and ACR20 (i.e. tender and
swollen joint counts, patient’s and assessor’s global as-
sessment measurements, acute-phase reactant and HAQ)
using the linear increments method of Diggle et al. [31, 32]
to handle the missingness. As the results obtained using
this approach were qualitatively the same as that of the
multiple imputation approach adopted, we report only the
findings from the standard multiple imputation analyses.
The effects of treatment on PsARC, ACR20 and DAS-28
responder measures were assessed at 3 and 6 months
using logistic regression, controlling for age, sex and
disease duration. Intention to treat (ITT)-type analyses
were performed on the imputed data from all randomized
patients. Additionally, completer analyses were performed
on those who completed 6 months of treatment. The
estimates are presented as odds ratios (OR) with 95%
CIs for the effect of MTX. Robust S.E.s were used through-
out to adjust for the different geographical regions in the
model. A pre-planned subgroup analysis investigating
whether the treatment effect varies with disease subtype
(i.e. oligoarticular and polyarticular) was performed by
adding the interaction term between treatment and dis-
ease subtype (oligoarticular and polyarticular) to the
models. This was an exploratory pre-planned subgroup
analysis, as the study was not powered to take account
of these subgroups.
The individual component data (tender and swollen joint
counts, patient’s and assessor’s global assessment
measurements, ESR, CRP, pain and HAQ) were evaluated
by linear regression models, and the point estimates
are b-coefficients with robust S.E.s accounting for
geographical clustering. These models controlled for the
individual’s baseline, age, gender and disease duration.
Statistical significance was determined at the 5% level
using a two-sided test throughout.
Ethics review
The trial was approved by the South East Multi-Centre
Research Ethics Committee and by local research ethics
committees at each centre. All enrolled patients gave
written informed consent.
Results
Recruitment, patients and treatment
Four hundred and sixty-two patients were screened at
22 rheumatology units from 13 January 2003. Two hun-
dred and forty-one patients were not enrolled; 148 of
these were ineligible and 93 did not consent (Fig. 1).
Two hundred and twenty-one patients were recruited.
Follow-up was completed by 3 July 2008 and the data
validated in 2009. One hundred and nine patients were
randomized to receive MTX and 112 patients were rando-
mized to receive placebo. Table 1 summarizes the char-
acteristics of the randomized patients.
Follow-up, reported in accordance with Consolidated
Standards of Reporting Trials (CONSORT) recommenda-
tions, is shown in Fig. 1. Forty-four patients were lost to
follow-up (21 receiving MTX and 23 receiving placebo).
Twenty-six patients discontinued treatment (14 receiving
MTX and 12 receiving placebo). Overall 23% of follow-up
data were missing at 6 months. The missing data were
imputed for the ITT analysis.
The target dose of 15 mg weekly MTX was achieved at
some point in the trial by >90% of patients receiving
active treatment. At 3 months, 93% of patients receiving
MTX were taking 15 mg weekly. At Month 5, 78% were
taking 15 mg with 11% receiving higher dosages (17.5 and
20 mg weekly) and 11% lower doses (7.5, 10 and 12.5 mg
weekly). One hundred and seventy-nine (81%) patients
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FIG. 1 CONSORT flowchart for MIPA trial.
TABLE 1 Details of patients enrolled
MTX (n=109) Placebo (n=112)
Gender, females : males, n (%) 53 (49) : 56 (51) 44 (39) : 68 (61)
Ethnicity, white European/other, n (%) 105 (96)/4 (4) 109 (97)/3(3)
Age, mean (S.D.), years 46 (13) 51 (11)
Disease duration, years 1 (15) 1 (16)
Smoking status
Never, n (%) 57 (53) 51 (45)
Previous, n (%) 23 (21) 38 (34)
Current, n (%) 28 (26) 23 (21)
Height, cm 170 (162177) 170 (162178)
Weight, kg 83 (7496) 86 (7497)
Pattern of arthritis, oligoarticular/polyarticular disease, n (%) 38 (35)/71 (65) 41 (37)/71 (63)
Previous SSZ treatment, n (%) 25 (23) 22 (20)
Concomitant analgesics, n (%) 10 (9) 13 (12)
Concomitant NSAIDs, n (%) 89 (82) 90 (80)
Tender joint count, range 068 9 (415) 11 (618)
Swollen joint count, range 066 6 (312) 6 (211)
ESR, mm/h 15 (728) 12 (624)
CRP, mg/dl 7 (516) 9 (519)
HAQ, range 03 0.88 (0.381.50) 1.13 (0.631.63)
Patient’s global assessment, 100-mm VAS 47 (3070) 49 (2869)
Assessor’s global assessment, 100-mm VAS 39 (2856) 41 (3057)
Pain, 100-mm VAS 36 (2559) 42 (2765)
Medians (interquartile range) are shown for clinical variables, unless otherwise mentioned.
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received concomitant NSAIDs (89 patients receiving MTX
and 90 placebo). Commonly used NSAIDs were diclofe-
nac (59 patients) and ibuprofen (35 patients); 35 patients
received coxibs.
Global indices in all randomized patients
ITT analyses of global indices using logistic regression
(adjusted for age, sex and disease duration) found no stat-
istically significant treatment effect with PsARC (OR 1.77,
95% CI 0.97, 3.23) after 6 months of MTX treatment
(Table 2). There was also no evidence of significant treat-
ment effects with ACR20 (OR 2.00, 95% CI 0.65, 6.22) or
DAS-28 (OR 1.70, 95% CI 0.90, 3.17). No global index
showed significant treatment effects at 3 months.
Individual outcome measures in all randomized
patients
ITT analyses using linear regression models (adjusted for
age, sex, disease duration and individual baseline score)
showed no evidence of a significant treatment effect of
MTX on joint counts, ESR, CRP, pain and HAQ scores
after 6 months treatment (Table 3). There were statistically
significant treatment effects on assessor global assess-
ments (coefficient 8.0, 95% CI 13.6, 2.4, P= 0.01)
and patient global assessments (coefficient 9.2, 95%
CI 17.0, 1.4, P= 0.02). No individual measure showed
a statistically significant treatment effect at 3 months.
Effects on skin and nails in all randomized patients
Baseline mean PASI scores were similar in the MTX (mean
3.76, 95% CI 2.83, 4.78) and placebo groups (3.79, 95%
CI 2.79, 4.78). Despite these low initial PASI scores, the
ITT analysis showed mean PASI scores in all randomized
patients fell to 2.22 (95% CI 1.62, 2.82) with MTX and
3.13 (95% CI 2.34, 3.92) with placebo. Linear regression
analysis, adjusted for age, sex, disease duration and
baseline PASI score, showed a significant reduction with
MTX compared with placebo (adjusted treatment
difference 0.93; 95% CI 1.71, 0.15; P= 0.02).
We also analysed PASI-75 response rates and nail
scores. The ITT analysis showed no significant differences
in PASI-75 response rates using logistic regression ana-
lyses (adjusted for age, sex and disease duration)
(OR 1.26, 95% CI 0.58, 2.72). Nail scores showed no
evidence of a treatment effect in any patient group at
3 and 6 months.
Valid compliant completer analyses
These analyses excluded patients who were lost to
follow-up, discontinued treatment or who met a pre-
defined reason for exclusion from analysis (Fig. 1).
Logistic regression (adjusted for age, sex and disease
duration) showed that at 6 months the OR of PsARC re-
sponses with MTX in these patients reached statistical
significance (OR 2.33, 95% CI 1.13, 4.84, P= 0.02).
However, there was no evidence of a treatment effect
on ACR20 (OR 1.67, 95% CI 0.74, 3.78, P= 0.22) and
DAS-28 responses (OR 2.07, 95% CI 0.98, 4.38,
P= 0.06). There was no evidence of a significant treatment
effect in any global index at 3 months. A more detailed
completer analysis is given in supplementary Section SA,
available as supplementary data at Rheumatology Online.
Impact of polyarticular disease
We examined whether effect of treatment on global
indices (PsARC, ACR20, DAS-28) varied between disease
subtype: polyarticular disease (initially more than four swol-
len joints) and oligoarticular disease (initially four or less
swollen joints). We included an interaction term between
treatment and disease subtype on each global index in the
ITT analysis of all randomized patients. This showed that
treatment effect on global indices did not vary between
disease subtype (P= 0.574 for interaction). Details of the
effect of disease subtype on individual outcome measures
are given in supplementary Section SB, available as
supplementary data at Rheumatology Online.
Adverse effects
In 16 patients, adverse effects were the principal reason
for withdrawal from the trial (9 MTX, 7 placebo); they were
also a secondary reason in 3 other patients (2 MTX, 1
placebo) in whom problems with persisting disease
activity stopped them from continuing treatment. Seven
withdrawals (five MTX, two placebo) were attributed to
potential MTX toxicity. Common adverse events (>5%
of one treatment arm) comprised nausea and vomiting
(38 patients receiving MTX, 16 patients receiving pla-
cebo), respiratory tract infections (31 MTX, 25 placebo),
abdominal pain (16 MTX, 6 placebo) and abnormal liver
function tests (12 MTX, 2 placebo).
Discussion
Our ITT analysis of all randomized patients in MIPA found
no statistically significant evidence that 6 months of MTX
treatment was more likely than placebo to improve any
rheumatology-related global response index in PsA, al-
though the effect sizes were in the direction of improve-
ment. In addition, there was no evidence that MTX had
significant benefits on objective measures of synovitis
including joint counts, ESR and CRP levels. We conse-
quently conclude that there is presently no evidence that
MTX improves inflammatory synovitis in active PsA; this
would be required for a true disease-modifying effect.
However, MTX did significantly improve assessors’ and
patients’ global assessments, suggesting it may have
TABLE 2 Effect of MTX on PsARC and other global indi-
ces in ITT analysis of all randomized patients
Global index OR (95% CI) P-value
PsARC 1.77 (0.97, 3.23) 0.06
ACR20 responders 2.00 (0.65, 6.22) 0.23
DAS-28 responders 1.70 (0.90, 3.17) 0.10
ORs were adjusted for age, sex and disease duration.
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symptom-modifying effects. It also showed a positive
effect on psoriasis skin scores, consistent with its
known efficacy in psoriasis; the benefit was relatively lim-
ited in our patient group because of their relatively low
initial skin scores [33].
Valid compliant completer analyses are generally re-
garded as suboptimal because they tend to overestimate
treatment effects due to selective withdrawal for lack of
efficacy in the placebo group. Conversely, this means they
are extremely sensitive at detecting any evidence for a
treatment effect. In our analysis of valid compliant comple-
ters, the PsARC, which is particularly sensitive to changes
in patients’ global responses, showed borderline improve-
ment. However, ACR20 and DAS-28 scores, which place
greater emphasis on joint counts, continued to show
no significant treatment benefits. New global measures
for PsA are being developed, which may provide different
perspectives on treatment in the future [3437].
Two previous placebo-controlled RCTs evaluated MTX
in PsA. High-dose (13 mg/kg) i.v. MTX, studied in 21 pa-
tients, reduced joint swelling and tenderness and the ESR.
However, seven patients had treatment-related leuco-
penia and one died, suggesting unacceptable toxicity
[38]. Low-dose oral MTX (7.515 mg/week) was studied
in 37 patients. Only physician global assessments and
skin psoriasis improved with treatment, replicating
the findings in MIPA [39]. Another RCT of 35 patients
compared immediate MTX with treatment delayed by
3 months in early PsA [40]. All clinical variables improved
over time and there was evidence that tender and swollen
joint counts improved more rapidly with early MTX.
Another RCT, also involving 35 patients, compared MTX
with ciclosporin and found similar improvements with both
[41]. A final RCT of 72 patients compared the impact of
adding ciclosporin to MTX therapy in PsA. In that trial,
both groups improved, and the only significant treatment
effect was on PASI scores [42]. None of these five trials
provides strong evidence in favour of MTX in PsA.
Systematic reviews of MTX in PsA also underline the
paucity of evidence [43, 44].
We consider that effective DMARDs in PsA should
reduce joint counts in direct head-to-head comparisons
with placebo. MIPA shows no evidence that oral MTX has
such effects. There was also no evidence that MTX
reduced joint counts in the only comparable trial of oral
MTX [39], five trials of SSZ and one trial of auranofin
[19, 4549]. The LEF trial in PsA did show treatment sig-
nificantly improved swollen and tender joint counts com-
pared with placebo [13]. We conclude that the evidence
that either MTX or SSZ has DMARD-like effects in PsA is
inconclusive. Despite the negative results seen in MIPA, it
is possible that MTX might be effective in some circum-
stances in patients with PsA. First, giving higher doses of
MTX for longer periods of time might have given positive
results. However, in RA, placebo-controlled RCTs show
15 mg weekly or less MTX is effective within 3 months [50],
suggesting a major treatment effect is unlikely to be over-
looked at the doses and duration used in MIPA. Secondly,
the inclusion criteria for MIPA allowed patients with fewerT
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active joints to be enrolled compared with some other PsA
trials. For example, trials of SSZ [19], MTX [39] and LEF
[13] all required at least three active joints. However, most
patients in MIPA were more active than the minimum entry
requirement and, as discussed in detail below, patients
with polyarticular PsA did not show a better response to
MTX. MIPA was designed as a pragmatic trial evaluating
the use of MTX in current clinical care, and in this context
it is important to note that it enrolled similar patients to
those reported in observational studies of routine practice
[51]. Finally, MIPA might have been too small to detect the
effect of MTX. The sample size calculation for MIPA used
PsARC responder rates from previous PsA trials.
However, using multiple imputation methods makes it in-
appropriate to give individual responder rates in the ana-
lysis of all randomized patients, as the imputation
methods create 20 imputations. Consequently, we have
used OR to report a point estimate for the imputed data.
The initial sample size calculation would have given an OR
of 2.7, which is the minimal OR given by agents thought to
be effective in PsA on the basis of published trials. The
results of MIPA lay between ORs of 1.8 and 2.3 (for all
patients and completers, respectively). In contrast, trials
of effective agents give strong effects; for example, the
LEF trial achieved an OR of 3.4 [13] and an etanercept trial
reported an OR >20 [8]. Although MIPA many have been
too small to detect minimal improvements in the PsARC,
the clinical benefit of such effects is questionable. We
believe a larger trial would not only be impractical but
also would be unwarranted in the face of more effective
alternatives.
The subgrouping of PsA patients creates complex ana-
lytical issues. Our pre-specified subgroup analyses
did not provide strong evidence that disease subtype
(polyarticular or oligo-articular) had a major impact on
treatment outcomes. However, there are other PsA sub-
groups, including some patients who meet criteria con-
ventionally used to define trial active RA [52]. Further
subgroup analyses provide some evidence that the sub-
group of PsA patients who meet the criteria for trial active
RA MTX had more impact on tender joint counts.
Conventional concerns about subgroup analysis [53]
mean caution is required in drawing conclusions from
our subgroup analyses. However, it is possible that the
positive results in the LEF trial in PsA reflect a greater
preponderance of RA-like PsA patients in that trial.
Withdrawals and the imputation of missing data might
explain our negative results. However, the placebo
6-month completion rate in MIPA was better than the
45% reported in the LEF trial [13], though lower than the
78% reported in the SSZ trial [19]. Overall, there is no
evidence that completion rates were particularly low in
MIPA. We used multiple imputation methods to account
for missing data and adjusted our analyses for baseline
variables. Additionally, the robustness of our imputation
analyses to missing data was assessed by carrying out
further sensitivity analyses using the linear increments
method. We consider it unlikely that the missing-at-
random assumption or other aspects of the imputation
method are likely to explain the non-significant findings
of MIPA.
MIPA took a decade from inception to completion.
Many specialists were unwilling to participate because
they believed that the efficacy of MTX was established
and believed a placebo-controlled trial was unwarranted.
With treatments of proven efficacy the case for placebo-
controlled trials is weak [54, 55], but this is not the case for
MTX in PsA. Ineffective treatments in PsA expose patients
to risks of adverse events that may cause more harm than
short-term placebo therapy [56]. Observational studies
cannot replace placebo-controlled RCTs because, in a
variable disease like PsA, treatment effects cannot be dis-
entangled from regression to the mean. Observational
studies of MTX in PsA [51, 57] mirror the changes in
MIPA, suggesting their effects are best explained by re-
gression to the mean.
There is strong evidence that low-dose oral MTX is ef-
fective in adults with RA [50]. It is also effective in juvenile
arthritis [58]. We have found no evidence that MTX is ef-
fective in other forms of adult non-rheumatoid inflamma-
tory arthritis. MIPA provides no evidence that it is effective
in PsA, and other RCTs suggest that oral MTX is ineffect-
ive in early undifferentiated arthritis [59] and AS [60]. In
contrast, biologics like TNF inhibitors appear effective in
a broad range of inflammatory arthropathies. As MTX is
not licensed for PsA and two RCTs have now provided
insubstantial evidence of its benefit for treating synovitis,
we therefore believe PsA is best managed using effective
licensed conventional drugs like LEF or biologics. We also
think that guidelines for treating PsA need to be revisited
so that the sequencing of conventional drugs before bio-
logics are used is re-evaluated.
Several unanswered questions remain. First, treating
PsA involves managing all its different components [61]
and also its skin involvement, which responds to MTX.
Therefore many patients with PsA may need to receive
MTX. Secondly, there is some evidence that MTX may
be beneficial when used in combination with biologics in
PsA. The Swedish register shows that it increases the time
patients remain on treatment [62]. Thirdly, MTX might be
effective as part of an intensive treatment strategy along-
side other DMARDs. This possibility is currently being
evaluated in an ongoing UK trial: Tight Control of
Psoriatic Arthritis (TICOPA; NCT01106079). Finally, PsA
patients with a rheumatoid-like pattern of disease may
respond to MTX. As a consequence, there are justifiable
reasons for treating some patients with PsA with MTX,
even though there is insufficient evidence for it being a
standard treatment for all patients with PsA who need
their synovitis to be suppressed.
Rheumatology key messages
. Low-dose oral MTX does not improve synovitis in
active PsA.
. MTX has borderline symptom-modifying properties.
. There is insufficient evidence to support the use of
MTX as a standard treatment for PsA.
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Jaccoud’s arthropathy of the feet presenting as
bilateral non-healing interdigital ulcers
A 44-year-old woman presented with bilateral painful
ulcers on the fourth interdigital spaces of her feet that
had appeared over the last 10 months and impaired
her gait. She had a clinically stable SLE and was on oral
prednisone and HCQ. Physical examination revealed a
painless and reducible medial deviation of both fifth toes
with disarticulated distal phalanges. Within each ulcer, an
eroded and spiky bone end was protruding into the inter-
digital space and pressing towards the lateral aspect of
the fourth toe (Fig. 1A, arrow). A reducible ulnar deviation
of the fingers of both hands was also observed (Fig. 1B).
Blood tests showed no signs of disease activity.
Radiographs of the hands and feet demonstrated multiple
reversible joint deformities in the absence of erosions
(Fig. 1C). Jaccoud’s arthropathy of the hands and feet
was diagnosed. The patient underwent selective surgical
amputation of the distal phalanges of the fifth toes, which
led to ulcer healing in weeks, with no relapse after a 1-year
follow-up.
Disclosure statement: The authors have declared no con-
flicts of interest.
Ignasi Pau-Charles1, Merce` Alsina1 and
Jose´ M. Mascaro´ Jr1
1Department of Dermatology, Hospital Clı´nic  Universitat de
Barcelona, Barcelona, Spain.
Correspondence to: Ignasi Pau-Charles, Department of
Dermatology, Hospital Clı´nic  Universitat de Barcelona,
Villarroel 170, 08036 Barcelona, Spain.
E-mail: ignasi.pau@gmail.com
FIG. 1 Jaccoud’s arthropathy of the hands and feet.
(A) Clinical appearance of the interdigital ulcer on the left foot, with the eroded and spiky end of the fractured distal
phalanx protruding from within and pressing towards the lateral aspect of the fourth toe. (B) Reducible ulnar deviation of
the fingers of both hands. (C) Non-erosive medial deviation of the MTP joints, associated with non-erosive subluxation of
the distal interphalangeal joints of the fifth toes with fractured distal phalanges.
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